Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.46 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28169484 | 0.98 | TSHR (0.56) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL1634259 | 0.85 | L3MBTL1 (0.61) | TSHRMAPK1MAPTPKML3MBTL1 | |
| Hydrochloric Acid SCHEMBL1277707 | 0.84 | L3MBTL1 (0.59) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL28244904 | 0.81 | TSHR (0.58) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL487351 | 0.81 | MAPK1 (0.58) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL27958762 | 0.81 | TSHR (0.58) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL10857754 | 0.80 | TDP1 (0.62) | TSHRMAPK1MAPTPKMLMNA | |
| SCHEMBL3840810 | 0.80 | MAPT (0.54) | TSHRMAPK1MAPTPKML3MBTL1 | |
| SCHEMBL9387603 | 0.79 | TDP1 (0.55) | TSHRMAPK1MAPTLMNAALDH1A1 | |
| SCHEMBL29702896 | 0.79 | TDP1 (0.55) | TSHRMAPK1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102388044-A | Heterocyclic inhibitors of histamine receptors for the treatment of diseases | KALYPSYS INC | 2012-03-21 | — | — | CN | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2324029-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009038847-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885MAPK1 2185/4885MAPT 2336/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885MAPK1 2185/4885MAPT 2336/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | TSHR 1282/4885MAPK1 400/4885MAPT 3899/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | TSHR 654/4885MAPK1 1453/4885MAPT 4601/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885MAPK1 2185/4885MAPT 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.